Format:
1 online resource
Edition:
2nd ed
Edition:
Online-Ausg. 2013 Electronic reproduction; Available via World Wide Web
ISBN:
9781118410875
,
9781405196253
,
129915803X
,
1118410904
,
9781299158030
,
9781118410905
Content:
Includes bibliographical references and index
Content:
Managing patients with thrombotic vascular disease is complex and challenging: Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis-even with the evolution in our understanding of the pathobiology of thrombosis.There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents Now more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other profes
Note:
Rev. ed. of: Therapeutic strategies in thrombosis / edited by Steen Dalby Kristensen, Raffaele De Caterina, and David J. Moliterno. 2006
,
Title page; Copyright page; Contents; Contributors; Foreword; Preface; CHAPTER 1: Arterial thrombosis: a brief overview; Introduction; Pathogenesis of arterial thrombosis; Platelets; Coagulation system; Effects of the severity of vessel wall damage and local geometry on the thrombotic response to atherosclerosis; Inflammation in arterial thrombosis; Platelets as circulating commodities in vascular disease; Summary; Acknowledgements; References; CHAPTER 2: Aspirin; Introduction; Mechanism of action of aspirin in inhibiting platelet function; Pharmacokinetics; Pharmacodynamics
,
Effects on TXA2 and PGI2 biosynthesisEffects of aspirin not related to COX-1 inactivation; Drug interactions; Interindividual variability in response to low-dose aspirin; Efficacy and safety of low-dose aspirin; Prevention and treatment of atherothrombosis in high-risk patients; Patients at intermediate risk of vascular complications; Low-risk subjects; Summary; References; CHAPTER 3: Platelet ADP P2Y12 inhibitors: thienopyridines; Introduction; The ADP receptor; Thienopyridine ADP P2Y12 receptor antagonists; Ticlopidine; Clopidogrel; Mechanism of action; Pharmacodynamics; Clinical uses
,
Dosing and platelet responsivenessPharmacogenomics; Drug interactions; Stent thrombosis and clopidogrel duration; Perioperative bleeding and clopidogrel timing; Prasugrel; Mechanism of action; Platelet responsiveness and prasugrel dosing; Clinical studies; Summary; References; CHAPTER 4: Platelet ADP P2Y12 inhibitors: nonthienopyridines; Introduction; Ticagrelor; Mechanism of action; Pharmacokinetics; Clinical trials; Cangrelor; Pharmacodynamics; Clinical studies; Future agents; Elinogrel; BX 667; Summary; References
,
CHAPTER 5: Cilostazol and dipyridamole: more than weak inhibition of plateletsIntroduction; Cilostazol; Dipyridamole; Summary; References; CHAPTER 6: Interrelationship of thrombin and platelets: the protease activated receptor-1; Introduction; Thrombin and its biology; Platelet physiology and receptors; Protease activated receptors; Structure and activation of PAR-1; Role of PAR-1 inhibitors in atherothrombosis; Aprotinin and PAR-1; Matrix metalloproteinases and PAR-1; PAR-1 in vasomotor tone, smooth muscle cells, and cardiomyocytes; Summary; References
,
CHAPTER 7: Glycoprotein IIb/IIIa inhibitorsIntroduction; Role of glycoprotein IIb/IIIa in mediating aggregation and facilitating coagulation; Pharmacology of clinically available drugs; Clinical trials; Abciximab; Tirofiban; Eptifibatide; Comparability among agents; Role of glycoprotein IIb/IIIa inhibitors in the current-use of aspirin and P2Y12 oral receptor blockers and concluding remarks; References; CHAPTER 8: Unfractionated heparin and low molecular weight heparin in ischemic heart disease; Introduction; Pharmacology and mode of action
,
Unstable angina and non-ST-segment elevation myocardial infarction
,
Arterial thrombosis : a brief overview
,
Aspirin
,
Platelet ADP P2Y12 inhibitors - thienopyridines
,
Platelet ADP P2Y12 Inhibitors - non-thienopyridines
,
Cilostazol and dipyridamole- more than weak inhibition of platelets
,
The inter-relationship of thrombin and platelets - the protease activated receptor-1 (PAR-1)
,
Glycoprotein IIb/IIIa inhibitors
,
Unfractionated heparin and low-molecular-weight heparin in ischemic heart disease
,
Pentasaccharide derivatives
,
Intravenous direct thrombin inhibitors
,
Vitamin K antagonists
,
Oral direct thrombin inhibitors and oral Xa inhibitors
,
Thrombolytic therapy and concomitant antithrombotic therapies
,
Antithrombotic therapy in STEMI
,
Antithrombotic therapy in non-ST elevation acute coronary syndromes
,
Antithrombotic strategies in patients undergoing elective PCI
,
Antithrombotic management in patients with prosthetic valves
,
Stroke - thrombolysis and antithrombotic therapy
,
Atrial fibrillation : current and forthcoming antithrombotic therapies
,
Venous thromboembolism : pathophysiology, diagnosis and prophylaxis
,
Antithrombotic therapy in venous thrombosis and pulmonary embolism
,
Prevention and treatment of venous and arterial thrombosis in patients with specific conditions : diabetes, hypercoagulable states, pregnancy and renal insufficiency
,
Genetics of the response to antithrombotic drugs and the need for monitoring
,
Electronic reproduction; Available via World Wide Web
Additional Edition:
1118410874
Additional Edition:
1118410890
Additional Edition:
9781118410875
Additional Edition:
9781118410899
Additional Edition:
Erscheint auch als Druck-Ausgabe Therapeutic Advances in Thrombosis
Language:
English
Subjects:
Medicine
Keywords:
Thrombose
;
Therapie
;
Electronic books
DOI:
10.1002/9781118410875
Bookmarklink